The well known molecule p53 serves not only as a tumour suppressor, but also acts as a barrier to the generation of induced pluripotent stem (iPS) cells. Five papers online in Nature this week show that when p53 is removed from cell populations that often fail to reprogram there is a higher degree of success.
The iPS cell field is fast moving — just three years ago stem cells were created from fibroblasts thanks to the insertion of four viral factors. Teams have tweaked the method, removing one or more of those factors. Shinya Yamanaka and colleagues managed to induce pluripotency in cells lacking p53 even without one of the four factors, and using a method that avoids genome integration of the factors. Juan Carlos Izpisua Belmonte and co-workers also demonstrate that reprogramming in the absence of oncogenes such as c-Myc and Klf4 occurs more efficiently when inactivating both p53 and another tumour suppressor. Another team led by Konrad Hochedlinger show that deletion of p53 in populations that do not reprogram rescues their ability to produce iPS cells, and that very high efficiencies can be achieved using immortalized cell lines that lack p53.
Maria Blasco and colleagues show that p53 is critically involved in preventing the reprogramming of cells carrying various types of DNA damage, including short telomeres. They go on to demonstrate that eliminating p53 allows efficient reprogramming even when there is DNA damage. Meanwhile Manuel Serrano and his team look at a tumour suppressor locus and report that the locus limits reprogramming. Furthermore, ageing has an effect on this locus, which means reprogramming is less efficient in cells from older organisms.
Paper DOIs:
DOI: 10.1038/nature08235
DOI: 10.1038/nature08311
DOI: 10.1038/nature08285
DOI: 10.1038/nature08287
DOI: 10.1038/nature08290
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.